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Riding on the CREST of a Wave!‘‘It doesn’t surprise me that we got better results with
stenting in the US where we have had much broader
experience. North American surgeons do the job
better.’’Gary Roubin, Los Angeles Times February 26th 20101
The much heralded CREST trial (Carotid Revasculariza-
tion Endarterectomy vs Stenting Trial) reported outcome
data to the American Stroke Association International
Stroke Conference on Friday 26th February 2010.2 This
study (funded by the National Institute of Neurological
Diseases & Stroke with support from Abbott Laboratories)
randomised 2502 patients (asymptomatic n Z 1176, symp-
tomatic n Z 1326) to undergo either carotid endarterec-
tomy (CEA) or carotid artery stenting (CAS). The trial
started with the intention of only randomising symptomatic
patients, but because recruitment was slow, the protocol
was amended to include asymptomatic patients as well.3
CREST was not, however, powered to be a ‘stand alone’
randomised trial in asymptomatic patients. As with earlier
randomised trials, interventionists and surgeons had to
submit a track record before their centre was accepted;
CEA was performed using the technique preferred by indi-
vidual surgeons, while CAS practitioners had to use an
obligatory stent (Rx Acculink, Abbott Laboratories) and
embolic protection device (Rx Accunet System, Abbott
Laboratories). Primary endpoints were; (i) the 30-day risk
of death/stroke and/or myocardial infarction (MI) and (ii)
the rate of ipsilateral stroke out to 4 years.
The main conclusions from CREST1e8 were that; (i) the
primary endpoint (30-day risk of death/stroke/MI) was
similar 5.2% after CAS vs 4.5% after CEA, (Hazard Ratio: 1.18
(95%CI 0.82e1.68) pZ 0.38), (ii) peri-operative stroke was
significantly higher following CAS 4.1% after CAS vs 2.3%
after CEA (Hazard Ratio: 1.79 (95% CI 1.14e2.82) pZ 0.01),
(iii) peri-operative MI was significantly higher following CEA
1.1% after CAS vs 2.3% after CEA (Hazard Ratio: 2.0 (95%CI
1.06e3.8) pZ 0.03), (iv) more procedural strokes after CAS
tended to be classed as major and ipsilateral, (v) one year1078-5884/$36 ª 2010 European Society for Vascular Surgery. Publishe
doi:10.1016/j.ejvs.2010.03.015after the procedure, patients who suffered a peri-operative
stroke reported a poorer quality of life compared to those
suffering a peri-operative MI, (vi) cranial nerve injury was
significantly higher following CEA (4.8% vs 0.3%,
p < 0.0001), (vii) patients aged <70 years had better results
following CAS, while patients aged >70 years gained better
outcomes after CEA and (viii) the four year rate of ipsilat-
eral stroke (excluding peri-operative events) was very
similar (2.0% after CAS vs 2.3% after CEA, p Z 0.85).1e8
Not surprisingly, headlines in national newspapers
concluded that ‘‘CAS and CEA were equally as safe and
effective in terms of stroke prevention’’. 1,9 The latter
statement is, however, factually incorrect because EVA-3S,
ICSS and now CREST have all shown that CAS was associated
with a significantly higher risk of procedural stroke (almost
a two fold excess risk). Notwithstanding this, the Millenium
Research Group (quoted as the global authority on medical
technology market intelligence5) predicted that CREST
would ‘‘support growth in carotid stenting by more than
10% over the next five years’’. If past experience is anything
to go by, that could be a significant underestimation?
Given the occasionally rancorous past history regarding
the performance and interpretation of randomised trials
comparing CEAwith CAS, CRESTwill inevitably attract a lot of
professional, industry and media scrutiny, not least because
their data were released on exactly the same day that ICSS
(still the largest randomised trial in symptomatic patients)
published completely different findings.10,11 In direct
contrast to CREST, ICSS (1713 recently symptomatic patients
randomised to CEA or CAS) observed significantly higher rates
of procedural death/stroke after CAS. On an ‘intention to
treat’ analysis, the 30-day risk of stroke/death was 8.5%
after CAS vs 4.7% after CEA (Hazard Ratio: 1.86 (95%CI 1.26e
2.74), pZ 0.00110). Using a ‘per-protocol analysis’, the 30-
day rate of death/stroke was 7.4% after CAS vs 3.4% after CEA
(Hazard Ratio: 2.16 (95%CI 1.4e3.310)). ICSS also reported
the results of a substudy involving 231 patients and observed
a statistically significant, threefold excess risk of new
ischaemic lesions on diffusion weighted imaging on post-
treatment MRI scans in patients randomised to CAS.11d by Elsevier Ltd. All rights reserved.
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patients from developing new ischaemic lesions.
When ICSS published its data, it became the fourth
consecutive large-scale, multicentre randomised trial that
failed to show statistical superiority for CAS (over CEA) in
the prevention of stroke in recently symptomatic
patients.10,12e14 In the New York Times, however, the ICSS
results were described as being ‘‘dismal’’.9 To other
observers, ICSS and the preceding trials reinforced intui-
tively held beliefs that CAS was inevitably going to incur
higher procedural risks in recently symptomatic patients,
while for others, the simple reason that CAS had not proved
superiority (or even equivalence) to CEA was because
European and Australasian CAS practitioners were somehow
technically inferior to their US counterparts.15 The latter
theme, undoubtedly provocative, was continued by Gary
Roubin who observed that ‘‘North American surgeons do the
job better’’ when asked by the Los Angeles Times to
explain why the ICSS and CREST results were so discordant.1
However, given that the most experienced CAS practi-
tioners incurred the highest procedural risks in the French
EVA-3S study,13 this does seem to be an unduly inflamma-
tory explanation for differences in published risk.
So has CREST settled the debate? Can we now (as sug-
gested by the deputy director of NINDS2) offer individualized
management decisions because ‘‘CREST provided doctors
and patients with much needed risk/benefit information to
help choose the best carotid procedure based on an indi-
vidual’s health history’’? To this observer, the data do not
(yet) support widespread and uncritical changes in practice
(especially in asymptomatic patients) until we are provided
with missing, vital information. Some readers will, of course,
dismiss this opinion as being that of a surgeon with a biased
agenda. However, while this observer believes that CAS will
evolve an increasingly important role in the management of
patients with carotid disease, there are important reasons
(so far ignored) why CREST reported ‘the lowest published
risks in any randomised trial to date’’,2,6 there are many
unanswered questions that need to be addressed before
clinicians can safely offer ‘individualized management
decisions’ and it is not inconceivable that uncritical inter-
pretation of the CREST data could fatally undermine ongoing
randomised trials in asymptomatic patients.
In comments attributed to Thomas Brott (CREST Prin-
ciple Investigator), the New York Times9 reported that
‘‘prior to the CREST trial, we did not really have the best
evidence, but that these results indicate that we have two
very safe and effective methods to prevent stroke’’. In the
same article, the New York Times offered no response to
comments by Martin Brown (ICSS Principle Investigator)
that three other large-scale, international trials had sug-
gested that ‘‘surgery was safer’’, while even less interest
was directed towards Brown’s assertion that the trial
cohorts were not statistically comparable.9 Accordingly,
the reader should not just consider what CREST (and the
other trials) have now told you. More important is to ask
what they have not told you. This missing information will,
ultimately, form a crucial element in helping to ‘‘individ-
ualize management decisions’’.
The obvious reason why CREST reported ‘the lowest
published risks in any randomised trial to date’’2,6 was
because it combined 30-day procedural risks for patientswith recent onset symptoms together with patients who
were neurologically asymptomatic. Procedural risks will
always be lower in asymptomatic patients and (given that
almost 50% of the CREST cohort was asymptomatic) it is
disingenuous to uncritically claim that CREST had much
lower procedural risks than SPACE, EVA-3S or ICSS. This is
because the latter studies only randomised recently
symptomatic patients, with no dilution of risk through the
inclusion of asymptomatic patients. Accordingly, and
before widespread changes in clinical practice can be
justified, it is imperative that CREST provides details about
the 30-day risk of death/stroke and death/stroke/MI after
stratification for symptom status. If emerging ‘grape vine’
rumours prove to be correct (which suggest that the 30-day
death/stroke rates were once again significantly higher in
symptomatic patients undergoing CAS), it is not inconceiv-
able that the procedural risks in symptomatic patients in
CREST may be more similar to those observed in ICSS, SPACE
& EVA-3S than some American surgeons and interventionists
might wish to accept. It is also important to note that most
of the peri-operative strokes following CAS in ICSS were
classed as ‘non-disabling’ and some observers consider that
this might be a relatively small price to pay for a less
invasive intervention. In CREST, the opposite seems to be
the case (ie more major, ipsilateral strokes after CAS). This
could explain why one year quality of life measures were
poorer in patients suffering a procedural stroke than in
patients suffering an MI.
The second important issue relating to CREST is how
these data will influence ongoing randomised trials. For
example, three (statistically powered) randomised trials
are currently evaluating the roles of CEA and CAS in
asymptomatic patients (ACT-1, SPACE II and ACST II).
However, uncritical interpretation of the CREST data could
fatally alter the equipoise of some trial participants (ie
leading to reduced trial recruitment because CAS is pref-
erentially offered to asymptomatic patients) at exactly the
same time that Neurologists and Stroke Physicians are
suggesting that improvements in best medical therapy have
significantly reduced the annual risk of stroke16 (ie moving
towards a strategy of restricting access to CEA and CAS for
the majority of asymptomatic patients). Until (if) TACIT
secures funding (sadly, less likely now), SPACE II remains
the only randomised trial in asymptomatic patients with
a third limb for ‘best medical therapy’. To this observer, it
would be disastrous if data from an underpowered cohort of
asymptomatic patients in CREST was used as mitigation for
not completing this study.
The third important issue is that CREST has provided no
information about one of the most important current issues
regarding stroke prevention; ie the need to offer CEA or CAS
within the hyperacute period after a patient suffers their
index stroke or TIA. Most health systems around the world
are now beginning to recognise that the highest risk period
for suffering a stroke is the first few days/weeks after
symptom onset, rather than just considering the first six
months as the high risk period. In the United Kingdom, NICE
now recommends that CEA be performed within 14 days of
symptom onset,17 while the UK Department of Health are
aiming for a 48 h treatment threshold.18 There is no
evidence to support a policy which encourages delays to
treatment (so as to reduce the procedural risk) as this
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prevention.19e21 Evidence derived from a reworking of the
pooled data from ECST, NASCET and the VA Trials suggest
that the surgeon who performs CEA within 14 days with a 10%
procedural risk might well attract uncritical, professional
censure, but he/she will prevent more strokes in the long
term than the surgeon who defers any intervention for 4
weeks and then operates with a 0% procedural risk.21
Accordingly, while CREST has been the first randomised
trial to report more favourable outcomes following CAS, it
would be inappropriate to completely ignore the results
from the preceding randomised studies in symptomatic
patients, inappropriate to conclude that there was no
need to continue with randomised trials in asymptomatic
patients and inappropriate to conclude that provided
symptomatic patients were offered CEA or CAS within 6
months of suffering their index symptom, surgeons/inter-
ventionists were somehow offering their patients optimal
practice. It is an incontestable (though sometimes unpal-
atable) fact that many more strokes will be prevented in
the community by focussing attention upon treating
symptomatic patients soon after they suffer their index
TIA or minor stroke, rather than trying to treat vast
numbers of asymptomatic patients. Notwithstanding the
logistical problems of identifying patients with asymp-
tomatic carotid disease, even if all were subjected to CEA
or CAS, at least 95% of all strokes destined to occur in the
community will still happen.22 Moreover, because 94% of
CEA/CAS procedures in asymptomatic patients are ulti-
mately unnecessary, the United States will continue to
spend $2.1 billion each year on (ultimately) unnecessary
interventions.22 It is, therefore, essential that we identify
clinical, imaging and plasma biomarkers that will identify
a high risk cohort of patients for suffering a stroke. It then
remains to be seen whether CAS or CEA becomes the
preferred intervention. Uncritical increases in the number
of interventions in asymptomatic patients (highly likely
following CREST) will do little to reduce the incidence of
stroke in the community, but it will contribute to an ever
increasing financial burden to health systems around the
world.
In conclusion, the rapid treatment of symptomatic
patients should remain the first priority of every health
system. We, therefore, need to pool data from CREST, ICSS,
EVA-3S and SPACE in order to perform individual patient
meta-analyses to determine which patient subgroups might
benefit most (or least) from CAS in the first few days after
symptom onset and those who might benefit most (or least)
from undergoing CEA in the same time frame. To suggest
that we now have enough evidence to individualize
management strategies based upon data from one trial that
pooled 30-day outcomes from symptomatic and asymp-
tomatic patients (whilst excluding important data from
three other trials incorporating 3312 patients) is just not
sustainable. To paraphrase Knut Rockne (b1888ed1931),
‘‘When you are riding on the crest of a wave, you are more
likely to miss something’’.Conflict of Interest
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